Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs

Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs

Abstract Background The patterns and determinants of saxagliptin use among patients with type 2 diabetes mellitus (T2DM) are unknown in real-world settings. We compared the characteristics of T2DM patients who were new initiators of saxagliptin to those who were new initiators of non-dipeptidyl pept...

Full description

Saved in:
Bibliographic Details
Main Authors: M Elle Saine, Dean M Carbonari, Craig W Newcomb, Melissa S Nezamzadeh, Kevin Haynes, Jason A Roy, Serena Cardillo, Sean Hennessy, Crystal N Holick, Daina B Esposito, Arlene M Gallagher, Harshvinder Bhullar, Brian L Strom, Vincent Lo Re
Format: Article
Language:English
Published: BMC 2015-04-01
Series:BMC Pharmacology and Toxicology
Subjects:
Diabetes mellitus
Saxagliptin
Dipeptidyl peptidase IV inhibitor
Pharmacoepidemiology
Online Access:https://doi.org/10.1186/s40360-015-0007-z
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items